Cancer and Immunomediated Inflammatory Diseases (IMIDs)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 10 June 2024 | Viewed by 1282

Special Issue Editor

E-Mail Website
Guest Editor
Division of Gastroenterology, ASST Fatebenefratelli-Sacco, via G.B. Grassi 74, 20157 Milano, Italy
Interests: gastroenterology; digestive endoscopy; inflammatory bowel disease (IBD)

Special Issue Information

Dear Colleagues,

Immune-mediated diseases represent a clinically heterogeneous group of disorders, affecting up to 10% of the population worldwide. Several immune-mediated diseases have been associated with an increased risk of cancer in the involved organs, such as inflammatory bowel diseases and colorectal cancer, primary sclerosing cholangitis and hepatobiliary cancer, celiac disease and small intestine cancer. Recently, immune-mediated diseases have been also associated with the risk of cancer in distant organs, both higher risk (e.g., ulcerative colitis and hepatobiliary cancer, rheumatoid arthritis and lymphoma) and lower risk (e.g., rheumatoid arthritis and breast, colorectal and prostate cancer). On the other hand, immune-mediated disorders and carcinogenesis have been demonstrated to share part of their inflammatory and immune-regulatory mechanism, such as inflammation-promoting TH17 dominance, dysfunctional Treg surveillance, inhibition of TH1 immunity, microbiota cross talk between colonized and distant organs.

More studies are needed to investigate the association between immune-mediated diseases with the risk of local and extra-local cancers. Moreover, cancer risk profiles for individual immune-mediated diseases need to be better understood.

In this Special Issue, primary research articles, clinical research articles and reviews are welcome. Research areas may include (but are not limited to) the following immune-mediated diseases and related risk of local and distant organ cancer:

  • Airways diseases (Asthma, allergic rhinitis, Interstitial pneumonia)
  • GI tract diseases (Inflammatory bowel disease, Celiac disease, Autoimmune gastritis, Primary biliary cholangitis, Primary sclerosing cholangitis, Autoimmune hepatitis, Autoimmune pancreatitis)
  • Skin diseases (Psoriasis, Vitiligo, Lichen planus, Bullous disorders)
  • Nervous system diseases (Multiple sclerosis, Guillain-Barre syndrome, Autoimmune neuropathies)
  • Endocrine diseases (Graves disease or autoimmune thyroiditis, Diabetes (type 1), Addison’s disease, Polyglandular syndromes)
  • Hematologic and cardiovascular system disorders (Idiopathic thrombocytopenic purpura, Vasculopathies, Rheumatic heart disease)
  • Musculoskeletal disorders (Ankylosing spondylitis, Rheumatoid arthritis, Psoriatic or enteropathic arthropathies, Polymyalgia rheumatica, Myositis, Myasthenia gravis)
  • Systemic immune-mediated diseases (Systemic lupus erythematosus, Systemic sclerosis, Sarcoidosis)
  • Autoinflammatory diseases (Familial Mediterranean Fever (FMF), Behçet’s disease, Adult onset Still’s disease)

Prof. Dr. Sandro Ardizzone
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • cancer risk

  • IMIDs
  • autoinflammatory diseases
  • autoimmune diseases
  • immune-mediated inflammatory diseases
  • immune-regulatory mechanism
  • carcinogenesis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


12 pages, 482 KiB  
Increased Risk of Renal Malignancy in Patients with Moderate to Severe Atopic Dermatitis
by Jongwook Oh, Hyun Ju Oh, Kyung-Do Han, Heon Yung Gee and Ji Hyun Lee
Cancers 2023, 15(20), 5007; - 16 Oct 2023
Viewed by 930
Background: Evidence for an association between atopic dermatitis (AD) and cancer is still insufficient. In particular, the association between the risk of renal malignancy and the severity of AD has not been thoroughly investigated. Objective: To investigate the risk of renal malignancy and [...] Read more.
Background: Evidence for an association between atopic dermatitis (AD) and cancer is still insufficient. In particular, the association between the risk of renal malignancy and the severity of AD has not been thoroughly investigated. Objective: To investigate the risk of renal malignancy and determine the association between AD severity and cancer risk using data from the Korean National Health Insurance Service (KNHIS) database. Methods: We performed a population-based cohort study using the National Health Claims database from the NHIS in Korea. Results: We found a statistically significant association between AD and overall malignancy (for mild AD, hazard ratio (HR): 1.061, 95% confidence interval (CI): 1.006–1.118; for moderate to severe AD, HR: 1.061, 95% CI: 1.014–1.11) compared with the no AD group. The moderate to severe AD group showed a significantly increased risk for renal malignancy (adjusted HR: 1.533, 95% CI: 1.209–1.944) compared with the no AD group. Limitations: Patient inclusion is solely based on diagnostic codes. We had no data about drug use, genetic factors, or other medical history that could affect the cancer risk. Conclusion: In our large population-based cohort study, moderate to severe AD was associated with increased risk of renal malignancy. Regular check-ups for renal malignancy are recommended in this population. Full article
(This article belongs to the Special Issue Cancer and Immunomediated Inflammatory Diseases (IMIDs))
Show Figures

Figure 1

Back to TopTop